Reteplase at the Molecular Interface: Mechanisms and Therapeutic Impact in Myocardial Infarction and Stroke Jeetendra Kumar Gupta Research Journal of Biotechnology, 2026 Reteplase, a recombinant plasminogen activator, is a modified version of Tissue-Plasminogen Activator (tPA). It has an altered structure, retaining Kringle 2 and Protease domains but lacks Finger, Epidermal Growth Factor (EGF) and Kringle 1 domains. The design of this molecule has provided Reteplase with certain advantages including longer half-life in the plasma (13–16 min.), lower fibrin affinity allowing for better clot penetration and non-glycosylated state allowing it to be administered by two boluses (usually 18 mg+18 mg, 30 min apart) regardless of body size. The molecular interactions at the interface between Reteplase and fibrin in clots provide a catalytic site for the activation of plasminogen to plasmin, resulting in degradation of the fibrin network and restoration of blood flow through the affected vessels. In comparison to Alteplase, Reteplase has shown earlier initiation of thrombolytic activity and possibly a higher rate of recanalization due to structural changes. Most recently, in patients with Acute Ischemic Stroke, the phase III RAISE Trial (2024) demonstrated that Reteplase was superior to Alteplase when administered less than or equal to 4.5 hrs post onset of symptoms, resulting in good functional outcomes. These results suggest that the primary mechanism for the observed benefits of Reteplase may be due to improved early recanalization. This review will discuss the molecular mechanisms of action, pharmacokinetics and expanding clinical use of Reteplase in Acute Myocardial Infarction (AMI) and Acute Ischemic Stroke, with particular emphasis on how Reteplase may be used to increase access to thrombolysis therapy in resource-poor areas while continuing to address issues of optimal dosing and expanded global availability.
Novel Cellular Signalling Axes in Neurodegenerative Diseases: From NLRP3 Inflammasome to Wnt/β-Catenin and Hippo-YAP Pathways Kuldeep Singh, Iftakhar Ahmad, Divya Jain, Tasmia Jahin Mim, Abdullah Al Noman, Md. Piar Rahaman Shihab, Suresh Babu Kondaveeti, Jeetendra Kumar Gupta, Pranay Wal Journal of Biochemical and Molecular Toxicology, 2026 Neurodegenerative diseases (NDs), including Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), and Parkinson's disease (PD), are characterised by impaired cellular homeostasis and progressive neuronal loss. Emerging evidence highlights the critical role of cellular signalling pathways in the progression and pathogenesis of these disorders. With a focus on the NLRP3 inflammasome, Wnt/β‐catenin, and Hippo‐YAP cascades, this review focuses on new signalling pathways linked to neurodegenerative disorders. Among them, the NLRP3 inflammasome is a crucial mediator of neuroinflammation, causing neuronal damage and persistent immune activation. In contrast, these pathways regulate neurogenesis, synaptic plasticity, and cell survival, offering potential neuroprotective functions. Dysregulation of these pathways disrupts cellular integrity, exacerbates disease progression, and represents a convergence point for therapeutic intervention. In NDs, knowing how these pathways interact offers fresh perspectives on disease processes and finds new targets for the creation of disease‐modifying treatments.
A Review on Neolamarckia cadamba - From Its Ancient Knowledge to Modern Science Ravindra Mishra, Jeetendra Kumar Gupta Current Drug Therapy, 2026 <P> In the herbal medicine system, N. cadamba is one of the most significant plants in the Rubiaceae family. N. cadamba contains numerous phytochemicals and secondary metabolites, in-cluding β-sitosterol, quinovic acid, cadambagenic acid, cadamine, and cadambine, which exhibit pharmacological and biological effects, making it a highly valuable medicinal plant. N. cadamba has demonstrated potential in managing conditions such as diabetes, epilepsy, hypertension, and other disorders, offering a natural alternative to synthetic chemical treatments. </P> <P> Over a century of research has been conducted to identify its phytochemicals and their effects. How-ever, due to a lack of appropriate model systems, only a small percentage (≤2%) of these compounds have been successfully marketed. Beyond its medicinal properties, N. cadamba is also valued as an ornamental plant with considerable cultural and religious importance. </P> <P> To stimulate interest and support the commercialization of N. cadamba phytochemicals, this review consolidates current knowledge on these compounds and highlights their pharmacological signifi-cance. By addressing the challenges of commercialization, including contentious issues, model sys-tem inadequacies, and solubility problems, the potential of N. cadamba as a cornerstone in herbal medicine can be fully realized. This comprehensive understanding and subsequent application could transform treatment options, providing natural and effective alternatives for managing and potentially curing various diseases.
Decoding microRNA-Protein Interaction Networks in Alzheimer’s Disease: Molecular Mechanisms and Clinical Implications Ravindra Mishra, Jeetendra Kumar Gupta Current Alzheimer Research, 2026 Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by memory loss, cognitive decline, and neuronal dysfunction. Despite thorough research efforts, effective disease-modifying treatments have yet to be discovered. MicroRNAs (miRNAs), small noncoding RNAs that control gene expression after transcription, have become key factors in AD development. Changes in miRNA levels influence critical molecular pathways such as amyloid precursor protein (APP) processing, tau phosphorylation, oxidative stress, neuroinflammation, and synaptic plasticity, all of which contribute to neuronal damage. By increasing β-secretase (BACE1) activity, downregulation of miR-29a/b and miR-107 encourages the buildup of amyloid-β (Aβ) and the development of plaques. Through the deregulation of the CDK5 and MAPK pathways, overexpression of miR-125b and decreased levels of miR-132/212 lead to tau hyperphosphorylation. While oxidative stress-associated miRNAs like miR-34a and miR- 21 worsen mitochondrial malfunction and neuronal death, pro-inflammatory miRNAs like miR-146a and miR-155 cause NF-κB-mediated signalling and glial activation. Circulating miRNAs found in blood and cerebral fluid are potential, minimally invasive indicators for tracking the course of a disease and making early diagnoses. Additionally, therapeutic manipulation with antagomiRs or miRNA mimics has the potential to prevent neurodegeneration and restore normal gene regulation. This review deciphers the molecular mechanisms underlying miRNA dysregulation in AD and explores their translational potential as biomarkers and therapeutic targets. A comprehensive understanding of miRNA-protein interaction networks could facilitate the development of targeted, precision- based interventions for Alzheimer’s disease.
A review on artificial intelligence in pharmaceutical sciences: opportunities and challenges Vivek Kumar, Saurav Kumar, Ravi Kumar, Nidhi Tiwari, Jeetendra Kumar Gupta Drug Development and Industrial Pharmacy, 2026 SIGNIFICANCE: The review aims to systematically explore the transformative impact of artificial intelligence (AI) on pharmaceutical sciences. It addresses key research questions regarding how AI accelerates drug development, enhances clinical trial design, optimizes manufacturing, and drives advances in personalized and precision medicine. METHODS: A comprehensive literature review was conducted. It synthesized recent studies, industry reports, and regulatory guidelines on AI adoption. Covered drug discovery, clinical trials, pharmacovigilance, manufacturing, supply chain management, and pharmacy education. It also critically examined barriers such as data quality, privacy, explainability, and the evolving regulatory landscape. RESULTS: AI accelerates pharmaceutical R&D, identification, lead optimization, ADMET (absorption, distribution, metabolism, excretion, toxicity) prediction, drug repurposing, and clinical trial analytics. It enables faster and more cost-effective development. Advancements in personalized medicine and individualized patient data are driving better patient outcomes. The students still ace continuing challenges in data interpretation, privacy, and regulatory issues. CONCLUSIONS: Ongoing AI advancements and evolving regulations are set to revolutionize pharmaceutical science. They will enable efficient, predictive, and patient-centered healthcare. Success will depend on integrating multi-omics, adopting explainable AI, and fostering collaboration among all stakeholders. Ultimately, AI promises safer, faster, and more precise drug delivery system. It benefits clinicians, researchers, and students.
Pharmacological Approaches and Innovative Strategies for Individualized Patient Care Amnesh Kumar Verma, Kuldeep Singh, Jeetendra Kumar Gupta, Shivendra Kumar, Divya Jain Recent Patents on Biotechnology, 2026 Personalized medicine is an evolving paradigm that aims to tailor therapeutic interventions to individual patient characteristics. With a growing understanding of the genetic, epigenetic, and molecular mechanisms underlying diseases, tailored therapies are becoming more feasible and effective. This review highlights the significant advancements in personalized medicine, focusing specifically on pharmacological strategies. The article explores the integration of genomics, transcriptomics, proteomics, and metabolomics in drug development and therapy optimization. Pharmacogenomics, the customization of drug therapy based on an individual's genetic makeup, receives particular emphasis. This leads to the identification of specific biomarkers that can predict therapeutic response, drug toxicity, and susceptibility to various diseases. Together with computational tools and artificial intelligence, these advancements contribute to tailored treatment plans for patients with conditions such as cancer, cardiovascular diseases, and neurological disorders. We also highlight the challenges and ethical considerations in implementing personalized medicine, such as data privacy, cost-effectiveness, and accessibility. We outline future prospects and ongoing research in this field, highlighting the importance of collaborative efforts between researchers, clinicians, pharmacists, and regulatory authorities.
Efficacy of Anti-Histaminic Agents in Asthma Management: A Critical Scientific Analysis Ekta Verma, Shweta Mishra, Jeetendra Kumar Gupta, Saheli Roy, Pranay Wal, Adarsh Sahu Combinatorial Chemistry and High Throughput Screening, 2026 Introduction: Allergic asthma is triggered by allergens and is commonly associated with elevated IgE levels. Histamine plays a pivotal role in its pathogenesis; however, the therapeutic role of antihistamines remains controversial. Since current treatments primarily provide symptomatic relief, this review evaluates the current status of antihistamines in asthma management, with a focus on pharmacological advances, natural therapies, and novel heterocyclic compounds. Method: A comprehensive literature search was systematically conducted across major databases, including PubMed, ScienceDirect, Scopus, and Web of Science. Studies evaluating the pharmacological potential of antihistamines, herbal compounds, and novel synthetic derivatives were included. Exclusion criteria encompassed studies unrelated to asthma or antihistamines, non-English publications, and editorials or conference abstracts lacking primary data. Results: Second- and third-generation antihistamines effectively alleviate symptoms of allergic asthma and can reduce corticosteroid use. Combining antihistamines with leukotriene receptor antagonists has been shown to further enhance treatment outcomes. Emerging evidence also suggests that heterocyclic compounds and plant-derived phytochemicals may serve as promising antihistamines and bronchodilators, although their clinical application remains limited. Discussion: Modern antihistamines provide added value as supportive agents in asthma management, particularly for allergic subtypes. Their improved pharmacological profiles reduce sedation and enhance patient compliance. The synergistic use of antihistamines with corticosteroids or leukotriene inhibitors exemplifies a shift toward multimodal therapy, while novel compounds continue to broaden therapeutic possibilities. Conclusion: Antihistamines are increasingly recognized as valuable adjuvants in asthma management. Although asthma remains incurable, advanced antihistamines and natural phytochemicals provide effective symptom relief. Continued research into novel compounds and integrated therapeutic strategies holds promise for improved disease control and enhanced quality of life.
A comprehensive review of drug-resistant epilepsy and animal models: Existing and emerging therapies and future research directions Aman Shrivastava, Jeetendra Kumar Gupta, Sumeet Dwivedi, Amit Anand, Darshana Sharma, Sonam Upadhyay, Prerna Chaturvedi Advanced Neurology, 2026 Epilepsy is a long-term neurological disorder that results in recurring, uncontrolled seizures. These kinds of seizures are caused by excessively high and irregular electrical discharge in the central nervous system. Epilepsy is among the most common neurological disorders, with approximately 50–70 new cases/100,000 people every year. This review critically examines the current landscape of pharmacological experimental animal models employed in the study of drug-resistant and refractory epilepsy, shedding light on the complexities of this multifaceted disorder. Through an extensive analysis of preclinical models, the review explores the diverse mechanisms underlying resistance to antiepileptic drugs, emphasizing the need for innovative therapeutic strategies. This review was conducted using a comprehensive search of databases, including PubMed, Scopus, and Web of Science, focusing on studies published from 2000 to 2024. Articles were selected based on relevance to drug-resistant epilepsy (DRE) models, emerging technologies, and translational potential, using keywords such as DRE, animal models, and epileptogenesis. In addition, emerging experimental approaches, such as optogenetics, chemogenetics, and advanced imaging techniques, were scrutinized. Furthermore, this review outlines innovative approaches, including novel pharmacotherapies, gene therapies, and precision medicine interventions, that hold promise for overcoming drug resistance. By synthesizing current knowledge and identifying gaps, this article aims to guide future research directions and stimulate innovative strategies for developing effective interventions for drug-resistant and refractory epilepsy. Ultimately, a comprehensive grasp of experimental models and innovative approaches is crucial for advancing our understanding of epilepsy pathophysiology and paving the way for more efficacious and personalized therapeutic interventions.
Challenges and future perspective of illicit drug sensors and strategies Konatham Teja Kumar Reddy, G. Dharmamoorthy, Jeetendra Kumar Gupta, L. Karpagavalli, Selvaraja Elumalai, Shaik Kareemulla, M. Jeevitha, Karthickeyan Krishnan Nanotechnology Based Sensing Platforms for Illicit Drugs, 2025
Monoterpenoid synergy: a new frontier in biological applications Md. Zamshed Alam Begh, Jishan Khan, Md Al Amin, Sherouk Hussein Sweilam, G. Dharmamoorthy, Jeetendra Kumar Gupta, J. Sangeetha, R. Lokeshvar, Mohamed H. Nafady, Irfan Ahmad, Mohammed Ali Alshehri, Talha Bin Emran Naunyn Schmiedeberg S Archives of Pharmacology, 2025
Osseous implications of proton pump inhibitor therapy: An umbrella review Abdullah S. Alanazi, Hadiah Almutairi, Jeetendra Kumar Gupta, Dibyalochan Mohanty, Deepankar Rath, Ali A. AlOdan, Ahmed Mahal, Mahalaqua Nazli Khatib, Shilpa Gaidhane, Quazi Syed Zahiruddin, Sarvesh Rustagi, Prakasini Satapathy, Hashem Abu Serhan Bone Reports, 2024
Synthesis Strategies of Doped QDs Konatham Teja Kumar Reddy, A. Venkata Badarinath, Jeetendra Kumar Gupta, Yeluguri Manikanta, Nagam Santhi Priya, G. Vamseekrishna, Jimmy Alex, Alapati Sahithi Engineering Materials, 2024
Cytotoxicity of Quantum Dots Based Nanocomposites Konatham Teja Kumar Reddy, N. Venkatesan, M. V. Saranya, Jeevanandham Somasundaram, Jeetendra Kumar Gupta, Nagam Santhi Priya, Prakash Srichand Sukhramani, Anasuya Patil Engineering Materials, 2024
Discovery and History of Quantum Dots Konatham Teja Kumar Reddy, B. Madhavi Latha, Jeetendra Kumar Gupta, A. Chaitanya, P. Srinivasa Babu, Vamseekrishna. G., Yeluguri Manikanta, Alapati Sahithi Engineering Materials, 2024
Recent perspective on the potential role of phytocompounds in the prevention of gastric cancer Md. Rezaul Islam, Abdur Rauf, Shopnil Akash, Ajoy Kumer, Md Sadique Hussain, Smrity Akter, Jeetendra Kumar Gupta, L.H. Thameemul Ansari, Mir Md. Mahfoj Islam Raj, Talha Bin Emran, Abdullah S.M. Aljohani, Waleed Al Abdulmonem, Rekha Thiruvengadam, Muthu Thiruvengadam Process Biochemistry, 2023
Role of Atrial Natriuretic Peptide in Abrogated Cardio protective Effect of Ischemic Postconditioning in Diabetic Rat Heart Latin American Journal of Pharmacy, 2022
Prodrugs of NSAIDs: A review Kamal Shah, Jeetendra K. Gupta, Nagendra S. Chauhan, Neeraj Upmanyu, Sushant K. Shrivastava, Pradeep Mishra Open Medicinal Chemistry Journal, 2017
Blood glucose lowering potential of Stem Bark of Berberis aristata Dc in Alloxan-induced diabetic rats Iranian Journal of Pharmacology and Therapeutics, 2010
Evaluation of antiulcer activity of Leucas lavandulifolia on mucosal lesion in rat Asian Journal of Pharmaceutical and Clinical Research, 2010
Patients with disturbed biorhythm and secondary beneficial effect of melatonin International Journal of Pharmacy and Pharmaceutical Sciences, 2009
Evaluation of antidiabetic and in vitro antioxidant activity of Leucas lavandulifolia Sm. (Labiatae) Indian Drugs, 2008
RECENT SCHOLAR PUBLICATIONS
A Review on Artificial Intelligence in Pharmaceutical Sciences: Opportunities & Challenges V Kumar, S Kumar, R Kumar, N Tiwari, JK Gupta Drug Development and Industrial Pharmacy, 1-49 , 2026 2026
Novel Cellular Signalling Axes in Neurodegenerative Diseases: From NLRP3 Inflammasome to Wnt/β‐Catenin and Hippo‐YAP Pathways K Singh, I Ahmad, D Jain, TJ Mim, AA Noman, MPR Shihab, ... Journal of Biochemical and Molecular Toxicology 40 (5), e70880 , 2026 2026
NF-κB Signaling Pathway: A Central Hub in the Pathogenesis and Therapeutic Targeting of Immunological Diseases Y Sharma, A Shrivastava, JK Gupta, R Mishra, A Dwivedi, P Chaturvedi, ... Gene Expression 25 (2) , 2026 2026 Citations: 2
The RhoA/ROCK pathway in vascular dysfunction and inflammation: Mechanisms and therapeutic targeting K Singh, D Jain, AK Tripathi, T Begum, M Muztaba, SS Khan, JK Gupta, ... European Journal of Inflammation 24, 1721727X261441093 , 2026 2026
Quercetin and Cancer: Molecular Mechanisms and Signaling Pathway Modulation for Therapeutic Benefits M Al Amin, M Zehravi, H Bouhenni, KA Siddika, JK Gupta, R Vodeti, ... Bentham Science Publishers , 2026 2026
Targeting NF-κB and JAK/STAT pathways in rheumatoid arthritis: emerging nanocarrier-based drug delivery approaches G Surendra, JK Gupta, E Susithra, AC Jesudoss Prabhakaran, ... Inflammopharmacology, 1-19 , 2026 2026
Efficacy of Anti-Histaminic Agents in Asthma Management: A Critical Scientific Analysis. E Verma, S Mishra, JK Gupta, S Roy, P Wal, A Sahu Combinatorial Chemistry & High Throughput Screening , 2026 2026
Gamma irradiation crosslinked fluorescent nanocarbon based biodegradable hydrogel for controlled release of antibiotics R Vodeti, M Rejili, VR Singamaneni, U Hani, F Fatima, J Kumar Gupta, ... PLoS One 21 (1), e0340351 , 2026 2026 Citations: 1
Molecular Mechanisms of Neurodegeneration: A Focus on Cholinergic Dysfunction and the Therapeutic Potential of Rivastigmine Derivatives K Singh, P Sethi, D Jain, JK Gupta, Z Waqar, B Singh, R Syed, M Tabish, ... Current Topics in Medicinal Chemistry , 2026 2026
Decoding microRNA-Protein Interaction Networks in Alzheimer’s Disease: Molecular Mechanisms and Clinical Implications R Mishra, JK Gupta Current Alzheimer Research , 2026 2026
A Review on Neolamarckia cadamba-From Its Ancient Knowledge to Modern Science R Mishra, JK Gupta Current Drug Therapy , 2026 2026
Emerging Roles of Small-molecule Derivatives in Modulating Neurodegenerative Pathways: From Molecular Targets to Therapeutic Applications K Singh, P Sethi, D Jain, JK Gupta, OA Alsaidan, SI Alzarea, A Kumar, ... Mini-Reviews in Medicinal Chemistry , 2026 2026
Advances in the Synthesis of GABAergic Modulators for Anxiety and Depression: Pathways and Potential Applications K Singh, P Sethi, D Jain, JK Gupta, OA Alsaidan, SI Alzarea, A Dubey, ... Current Neuropharmacology , 2026 2026
Insights into the Molecular Mechanisms of Neurodegenerative Diseases: Exploring Molecular Pathways and the Therapeutic Potential of Rivastigmine K Singh, P Sethi, M Kumari, JK Gupta, Z Waqar, D Jain, A Verma, A Bhatt, ... CNS & Neurological Disorders-Drug Targets , 2026 2026
Advances in nanomedicine strategies for modulating the tumor microenvironment: Recent progress and clinical perspectives TB Emran, M Al Amin, SO Rab, P Jahnavi, R Vodeti, JK Gupta, ... 3 Biotech 16 (1), 36 , 2026 2026 Citations: 2
Advances in polymeric nanoparticles for oral drug delivery: mechanisms, challenges, emerging trends, and preclinical to clinical perspectives M Zehravi, SL Khan, JK Gupta, P Jahnavi, RH Babu, N Vidiyala, ... 3 Biotech 16 (1), 35 , 2026 2026 Citations: 3
Biogenic Synthesis of SnO 2 Nanoparticles Using Albizia saman Leaf Extract for Visible Light-Driven Photocatalytic Dye Degradation and Antibacterial Applications C Parvathiraja, K Paulkumar, JK Gupta, L Mouni, TM Almutairi, ... Arabian Journal for Science and Engineering 51 (2), 1639-1649 , 2026 2026 Citations: 2
Multiple sclerosis: a comprehensive review of pathophysiology and combined natural-synthetic therapeutic strategies M Al Amin, M Zehravi, SH Sweilam, MR Molla, P Jahnavi, OM Bagade, ... 3 Biotech 15 (11), 384 , 2025 2025
Mechanistic insights into plant-derived natural compounds for the treatment of skin cancer: Targeting molecular signaling for therapeutic intervention A Pathak, G Surendra, SB Sridhar, P Jahnavi, JK Gupta, P Balaji, ... Pathology-Research and Practice, 156277 , 2025 2025 Citations: 1
A rare case of Aspergillosis in a goat. GS Bhullar, J Gupta, ND Singh INDIAN JOURNAL OF VETERINARY PATHOLOGY 49 (4) , 2025 2025
MOST CITED SCHOLAR PUBLICATIONS
Molecular Docking and In Silico Cogitation Validate Mefenamic Acid Prodrugs as Human Cyclooxygenase-2 Inhibitor K Shah, S Mujwar, JK Gupta, SK Shrivastava, P Mishra Assay and drug development technologies 17 (6), 285-291 , 2019 2019 Citations: 83
An Analysis Of The Most Recent Trends In Flavoring Herbal Medicines In Today's Market P Vishvakarma, S Mandal, J Pandey, AK Bhatt, VB Banerjee, JK Gupta Journal of Pharmaceutical Negative Results, 9189-98 , 2022 2022 Citations: 82
Natural products as drug leads: exploring their potential in drug discovery and development K Singh, JK Gupta, DK Chanchal, MG Shinde, S Kumar, D Jain, ... Naunyn-Schmiedeberg's Archives of Pharmacology 398 (5), 4673-4687 , 2025 2025 Citations: 75
Pharmacological importance of Cucumis melo L.: An overview VK Vishwakarma, JK Gupta, PK Upadhyay Asian Journal of Pharmaceutical and Clinical Research 10 (3), 8-12 , 2017 2017 Citations: 74
Advances in gene therapy approaches targeting neuro-inflammation in neurodegenerative diseases K Singh, P Sethi, S Datta, JS Chaudhary, S Kumar, D Jain, JK Gupta, ... Ageing research reviews 98, 102321 , 2024 2024 Citations: 68
Prodrugs of NSAIDs: A review K Shah, JK Gupta, NS Chauhan, N Upmanyu, SK Shrivastava, P Mishra The open medicinal chemistry journal 11, 146 , 2017 2017 Citations: 68
Development of atomoxetine-loaded NLC in situ gel for nose-to-brain delivery: optimization, in vitro, and preclinical evaluation D Mohanty, OA Alsaidan, A Zafar, T Dodle, JK Gupta, M Yasir, A Mohanty, ... Pharmaceutics 15 (7), 1985 , 2023 2023 Citations: 58
Synthesis and characterizations of Fe-doped NiO nanoparticles and their potential photocatalytic dye degradation activities S Minisha, J Johnson, S Mohammad Wabaidur, JK Gupta, S Aftab, ... Sustainability 15 (19), 14552 , 2023 2023 Citations: 53
Drug Repurposing Approach for Developing Novel Therapy Against Mupirocin-Resistant Staphylococcus aureus S Mujwar, R Deshmukh, RK Harwansh, JK Gupta, A Gour Assay and drug development technologies 17 (7), 298-309 , 2019 2019 Citations: 51
Blood glucose lowering potential of stem bark of Berberis aristata Dc in alloxan-induced diabetic rats JK Gupta, P Mishra, A Rani, PM Mazumder IRANIAN JOURNAL OF PHARMACOLOGY AND THERAPEUTICS (IJPT) 9 (1), 21-24 , 2010 2010 Citations: 51
Computational design and biological depiction of novel naproxen derivative K Shah, S Mujwar, G Krishna, JK Gupta ASSAY and Drug Development Technologies 18 (7), 308-317 , 2020 2020 Citations: 47
Role of cardiac renin angiotensin system in ischemia reperfusion injury and preconditioning of heart V Agrawal, JK Gupta, SS Qureshi, VK Vishwakarma Indian heart journal 68 (6), 856-861 , 2016 2016 Citations: 47
Potential benefits of methylcobalamin: A review JK Gupta, QS Sana Austin J Pharmacol Ther 3 (3), 1076-1080 , 2015 2015 Citations: 43
AI-driven insights into the microbiota: figuring out the mysterious world of the gut A Patil, N Singh, M Patwekar, F Patwekar, A Patil, JK Gupta, S Elumalai, ... Intelligent Pharmacy 3 (1), 46-52 , 2025 2025 Citations: 42
Anti-inflammatory and antinociceptive evaluation of newly synthesized 4-(substituted ethanoyl) amino-3-mercapto-5-(4-methoxy) phenyl-1, 2, 4-triazoles N Upmanyu, JK Gupta, K Shah, P Mishra Journal of Pharmacy and Bioallied Sciences 3 (2), 259-265 , 2011 2011 Citations: 42
Exploring the ancient wisdom and modern relevance of Chinese medicine: a comprehensive review K Singh, JK Gupta, D Jain, S Kumar, T Singh, S Saha Pharmacological Research-Modern Chinese Medicine 11, 100448 , 2024 2024 Citations: 39
Docking based screening of curcumin derivatives: A novel approach in the inhibition of tubercular DHFR S Mujwar, K Shah, JK Gupta, A Gour International Journal of Computational Biology and Drug Design 14 (4), 297-314 , 2021 2021 Citations: 39
Development of soft luliconazole invasomes gel for effective transdermal delivery: optimization to in-vivo antifungal activity S Kumari, OA Alsaidan, D Mohanty, A Zafar, S Das, JK Gupta, M Khalid Gels 9 (8), 626 , 2023 2023 Citations: 38
The role of aldose reductase in polyol pathway: an emerging pharmacological target in diabetic complications and associated morbidities JK Gupta Current Pharmaceutical Biotechnology 25 (9), 1073-1081 , 2024 2024 Citations: 35
Alkaloid-based modulators of the PI3K/Akt/mTOR pathway for cancer therapy: Understandings from pharmacological point of view FZ Mokhfi, M Al Amin, M Zehravi, SH Sweilam, UVNV Arjun, JK Gupta, ... Chemico-Biological Interactions 402, 111218 , 2024 2024 Citations: 33